JP2005068010A5 - - Google Patents

Download PDF

Info

Publication number
JP2005068010A5
JP2005068010A5 JP2003063378A JP2003063378A JP2005068010A5 JP 2005068010 A5 JP2005068010 A5 JP 2005068010A5 JP 2003063378 A JP2003063378 A JP 2003063378A JP 2003063378 A JP2003063378 A JP 2003063378A JP 2005068010 A5 JP2005068010 A5 JP 2005068010A5
Authority
JP
Japan
Prior art keywords
risedronate
pharmaceutical composition
unit dose
composition according
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003063378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005068010A (ja
Filing date
Publication date
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed filed Critical
Publication of JP2005068010A publication Critical patent/JP2005068010A/ja
Publication of JP2005068010A5 publication Critical patent/JP2005068010A5/ja
Pending legal-status Critical Current

Links

JP2003063378A 1997-07-22 2003-03-10 骨吸収を抑制する方法 Pending JP2005068010A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP50991499A Division JP3479780B2 (ja) 1997-07-22 1998-07-17 骨吸収を抑制する方法

Publications (2)

Publication Number Publication Date
JP2005068010A JP2005068010A (ja) 2005-03-17
JP2005068010A5 true JP2005068010A5 (enExample) 2005-06-16

Family

ID=27451690

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50991499A Expired - Lifetime JP3479780B2 (ja) 1997-07-22 1998-07-17 骨吸収を抑制する方法
JP2003063378A Pending JP2005068010A (ja) 1997-07-22 2003-03-10 骨吸収を抑制する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP50991499A Expired - Lifetime JP3479780B2 (ja) 1997-07-22 1998-07-17 骨吸収を抑制する方法

Country Status (31)

Country Link
EP (5) EP0998292B1 (enExample)
JP (2) JP3479780B2 (enExample)
KR (3) KR20030097610A (enExample)
CN (3) CN1299689C (enExample)
AT (2) ATE357921T1 (enExample)
AU (1) AU8493698A (enExample)
BG (1) BG66282B1 (enExample)
BR (1) BR9810779A (enExample)
CA (1) CA2294595C (enExample)
CY (2) CY1107535T1 (enExample)
DE (6) DE122006000009I1 (enExample)
DK (2) DK1175904T3 (enExample)
EA (1) EA004544B2 (enExample)
EE (1) EE05603B1 (enExample)
ES (3) ES2269014T3 (enExample)
HK (4) HK1042230A1 (enExample)
ID (1) ID24096A (enExample)
IL (1) IL133535A0 (enExample)
IS (3) IS5315A (enExample)
LU (2) LU91222I2 (enExample)
NL (2) NL300223I1 (enExample)
NO (1) NO20000323L (enExample)
NZ (1) NZ501807A (enExample)
PL (1) PL195272B1 (enExample)
PT (2) PT998292E (enExample)
SG (2) SG139556A1 (enExample)
SI (1) SI0998292T1 (enExample)
SK (1) SK932000A3 (enExample)
TR (1) TR200000145T2 (enExample)
UY (1) UY25950A1 (enExample)
WO (1) WO1999004773A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1798700A (en) 1998-12-25 2000-07-31 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions for treating osseous lesion in multiple myeloma
DK1178810T3 (da) * 1999-05-21 2005-07-11 Novartis Ag Anvendelse af bisphosphonsyrer til behandling af angiogenese
ES2337545T3 (es) * 1999-07-19 2010-04-27 Toray Industries, Inc. Farmacos para enfermedades periodontales.
US20010044427A1 (en) * 1999-12-20 2001-11-22 Sidney Mazel Pharmaceutical kit
WO2001046040A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Blister package for pharmaceutical treatment card
JP2004517800A (ja) * 2000-04-07 2004-06-17 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 両性イオンリン脂質およびビスホスホネートを含む独特の組成物および胃腸毒性を低減化したビスホスフェートデリバリーシステムとしての該組成物の使用
SI1296689T1 (sl) * 2000-06-20 2006-08-31 Novartis Ag Nacin dajanja pacientu bisfosfonatov
US8052987B2 (en) 2000-06-20 2011-11-08 Novartis Pharmaceuticals Corporation Method of administering bisphosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
KR20140021045A (ko) * 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
KR20060058134A (ko) * 2003-09-19 2006-05-29 화이자 프로덕츠 인코포레이티드 2-알킬리덴-19-노르-비타민 디 유도체 및비스포스포네이트의 조합을 포함하는 약학 조성물 및 방법
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
CA2622322A1 (en) * 2005-09-16 2007-03-22 Selamine Ltd Bisphosphonate formulation
ES2716525T3 (es) * 2010-12-06 2019-06-13 Effrx Pharmaceuticals Sa Formulaciones de bisfosfonatos efervescentes estables con características de solubilización rápida
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
EP0521388B1 (de) * 1991-07-01 1995-05-10 Gerhard Dr. Gergely Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung
AU661080B2 (en) * 1991-11-22 1995-07-13 Warner Chilcott Company, Llc Risedronate delayed-release compositions
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
HUT70210A (en) * 1992-06-30 1995-09-28 Procter & Gamble Pharma Use of phosphonates for the treatment of osteoporosis
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
CA2221416A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
JP2000511178A (ja) * 1996-05-17 2000-08-29 メルク エンド カンパニー インコーポレーテッド 発泡性ビスホスホネート製剤

Similar Documents

Publication Publication Date Title
JP2006504795A5 (enExample)
ES2247123T3 (es) Metodo para administrar bisfosfonatos.
HRP20130057T1 (hr) Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom
HRP20230272T1 (hr) Postupci za liječenje cistične fibroze
JP2013121983A5 (enExample)
HRP20161444T1 (hr) Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo
CA2434484A1 (en) Compositions comprising ibuprofen and diphenhydramine to treat pain-associated sleep disturbances
JP2002509888A5 (enExample)
IL205262A (en) Use of Risderdone Acid or its Pharmaceutical Salt to produce oral medication once a month for the prevention and treatment of osteoporosis
JP2013231087A5 (enExample)
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
HRP20100276T1 (hr) Gaboksadol za liječenje depresije i drugih afektivnih poremećaja
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
JP2005500298A5 (enExample)
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
JP2005519936A5 (enExample)
JP2002540148A5 (enExample)
RU2005105691A (ru) Пероральное введение кальцитонина
MXPA04004907A (es) Composiciones de acetaminofen.
RU2006131553A (ru) Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物